CQDM

Vega Bioimaging is a company focused on enhancing cancer diagnostics to ensure that patients receive tailored treatments, ultimately improving their survival rates and quality of life. It has developed a novel immunolabeling technology that employs nanobeads of various colors to target specific proteins, leading to more quantitative and precise biopsy analysis. This advanced approach facilitates better stratification of cancer patients and more accurate assessments of their eligibility for precision therapies. The Vega solution comprises three core components: a protein detection kit, a slide digitizing system that seamlessly integrates with existing microscopy platforms, and quantification software powered by artificial intelligence. Through these innovations, Vega Bioimaging aims to provide deeper insights into diseases and support the development of more effective cancer treatments.

NeuroTracker is a leading neurotechnology company specializing in cognitive training systems designed to enhance mental capabilities and performance. Backed by over 40 peer-reviewed studies and two decades of neuroscience research, NeuroTracker's patented platform utilizes multiple-object tracking to improve high-level cognitive functions such as situational awareness, attention, and executive function. The system is widely employed by clinicians and therapists in neurovision and rehabilitation, as well as by elite athletes, military personnel, pilots, and professional gamers seeking to boost their cognitive abilities. NeuroTracker's technology aims to transform lives, helping individuals of all backgrounds increase their concentration, focus, and response times, ultimately leading to heightened mental performance.

Oragenics is a biopharmaceutical company focused on developing novel antibiotics and treatments for infectious diseases. Its primary product candidate is an intranasal vaccine aimed at providing long-lasting immunity against SARS-CoV-2 and its variants.

Giiant Pharma is a preclinical-stage biotechnology company developing gut-restricted, tissue-targeted small molecule therapeutics for gastroenterology and inflammatory bowel diseases. Leveraging a proprietary Precision Delivery platform, it uses the gut microbiota to bioactivate and release active drug forms specifically in the lower GI tract, minimizing systemic exposure and potentially improving tolerability and efficacy. The company’s lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug designed to reduce inflammation in the colon. By focusing on localized delivery and reduced systemic exposure, Giiant aims to provide safer, more effective treatments for IBD and related GI conditions.

Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, focused on developing innovative therapies for bone-related diseases. Established in 2013, the company specializes in a prodrug platform that delivers therapeutics selectively to bone, addressing challenges associated with conventional drug delivery methods. Mesentech's lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic that aims to reverse bone loss associated with conditions such as osteoporosis and Duchenne muscular dystrophy. The company's proprietary technology enhances the delivery of small-molecule and biological drugs to the bone's surface and interior, allowing for more effective treatment while minimizing side effects. This approach is particularly significant given the inherent difficulty in accessing bone tissue due to its hard surface and low porosity. Mesentech's focus on selective drug delivery not only aims to improve treatment efficacy but also hopes to accelerate bone healing and address complications associated with low bone density disorders.

Founded in 2012, ImStar Therapeutics is a biotechnology company based in Vancouver, Canada. It focuses on developing treatments for amyotrophic lateral sclerosis (ALS), with a pipeline comprising IMS-088 and TDP-43 Associated NF-kB Activation Inhibitors.

Encycle Therapeutics, Inc. is a biotechnology company based in Toronto, Canada, that focuses on developing innovative drug candidates using its proprietary platform technology for the rapid synthesis of drug-like macrocycles and membrane-permeable nacellins. These nacellins are designed to target challenging intracellular protein-protein interactions, offering a potential alternative to traditional small molecules and biologics, such as monoclonal antibodies. The company has established collaborations with various pharmaceutical firms to build a screening library of nacellins, many of which demonstrate cell-permeable and drug-like characteristics. Encycle is actively pursuing the independent development of nacellins aimed at specific targets, including integrin alpha-4-beta-7 for inflammatory bowel disease and SMURF2 for fibrosis. Its lead program seeks to create orally bioavailable inhibitors of integrin alpha-4-beta-7 that promise improved safety and reduced immunogenicity compared to existing biologics targeting this protein.

KalGene Pharmaceuticals Inc. is a private biotechnology company based in Candiac, Canada, focused on developing precision medicine for the treatment of Alzheimer’s disease. Established in 2006, KalGene collaborates with leading clinician-scientists and academic institutions across North America and Europe. The company specializes in creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates. Through personalized medicine, KalGene seeks to predict patient responses to specific therapies before treatment begins, enabling physicians to tailor interventions based on individual biological signatures and needs.

InDanio Bioscience Inc. is a privately-held drug discovery company based in Toronto, Canada, specializing in the development of new chemical entities targeting nuclear receptor protein families. Established in 2008, the company utilizes a proprietary Ligand Trap system featuring 48 transgenic zebrafish lines, each expressing one of the human nuclear receptors, to facilitate the simultaneous evaluation of drug delivery, stability, specificity, tissue selectivity, and toxicity. This innovative approach enables the identification, extraction, and characterization of new hormonal regulators, as well as the discovery of tissue-selective drugs and their associated mechanisms of action. Through its advanced screening techniques, InDanio Bioscience aims to enhance the drug development process and contribute to the advancement of therapeutic options in the pharmaceutical industry.